Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Depreciation and Depletion (2016 - 2024)

Historic Depreciation and Depletion for Northwest Biotherapeutics (NWBO) over the last 10 years, with Q2 2024 value amounting to $500000.0.

  • Northwest Biotherapeutics' Depreciation and Depletion rose 2500.0% to $500000.0 in Q2 2024 from the same period last year, while for Jun 2024 it was $1.7 million, marking a year-over-year increase of 2142.86%. This contributed to the annual value of $1.7 million for FY2024, which is 1333.33% up from last year.
  • According to the latest figures from Q2 2024, Northwest Biotherapeutics' Depreciation and Depletion is $500000.0, which was up 2500.0% from $400000.0 recorded in Q1 2024.
  • Northwest Biotherapeutics' Depreciation and Depletion's 5-year high stood at $500000.0 during Q2 2022, with a 5-year trough of $2000.0 in Q2 2020.
  • Over the past 4 years, Northwest Biotherapeutics' median Depreciation and Depletion value was $400000.0 (recorded in 2022), while the average stood at $290230.8.
  • Within the past 5 years, the most significant YoY rise in Northwest Biotherapeutics' Depreciation and Depletion was 98000.0% (2020), while the steepest drop was 6666.67% (2020).
  • Over the past 4 years, Northwest Biotherapeutics' Depreciation and Depletion (Quarter) stood at $54000.0 in 2020, then surged by 640.74% to $400000.0 in 2022, then changed by 0.0% to $400000.0 in 2023, then increased by 25.0% to $500000.0 in 2024.
  • Its last three reported values are $500000.0 in Q2 2024, $400000.0 for Q1 2024, and $400000.0 during Q4 2023.